Prime Research

Latest Research

Biosimilar strategy for bevacizumab using MedDrive™

Avastin® (bevacizumab) from Genentech was first approved in 2004. It has received FDA approval for treatment of:1 advanced colon cancer (2004) advanced lung cancer (2006)…

Read More

Drug Pipeline Update: November 2021

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs…

Read More

MedDrive™ derives biosimilar savings from oncology monoclonal antibodies

MedDrive has identified cost-saving biosimilar strategies for three oncology biosimilars: rituximab (Rituxan®—reference drug) trastuzumab (Herceptin®—reference drug) bevacizumab (Avastin®—reference drug) All three of these drugs were…

Read More
Select a Research Type
Drug pipeline updates
Prime analysis
Scientific presentations
Loading …